Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Inventory (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Change in Inventory data on record, last reported at $124000.0 in Q3 2025.

  • For Q3 2025, Change in Inventory rose 103.52% year-over-year to $124000.0; the TTM value through Sep 2025 reached $4.1 million, up 192.52%, while the annual FY2024 figure was $2.2 million, 1.92% down from the prior year.
  • Change in Inventory reached $124000.0 in Q3 2025 per PLX's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $4.0 million in Q4 2024 and bottomed at -$3.5 million in Q3 2024.
  • Average Change in Inventory over 5 years is $430157.9, with a median of $124000.0 recorded in 2025.
  • Peak YoY movement for Change in Inventory: soared 1720.1% in 2021, then crashed 667.82% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $3.2 million in 2021, then crashed by 30.46% to $2.2 million in 2022, then crashed by 213.2% to -$2.5 million in 2023, then skyrocketed by 259.34% to $4.0 million in 2024, then tumbled by 96.93% to $124000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $124000.0 in Q3 2025, $1.6 million in Q2 2025, and -$1.7 million in Q1 2025.